Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 256 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Phase | EXPERIMENTAL | Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256. |
| Dose Expansion Phase: Group 1 | EXPERIMENTAL | Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study. |
| Dose Expansion Phase: Group 2 | EXPERIMENTAL | Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study. |
| Name | Type | Description |
|---|---|---|
| AMG 256 | DRUG | AMG 256 administered as an intravenous (IV) infusion. |
Inclusion Criteria: * Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age ≥ 18 years at the time of signing informed consent. * Life expectancy of \> 3 months, in the opinion of the investigator. * Participant must have histologically or ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AMG 256 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has been studied in adult subjects with advanced solid tumors. The drug is not approved and remains under investigation.
The specific molecular target of AMG 256 has not been disclosed. It is a small molecule modality being studied in oncology for advanced solid tumors. Without a disclosed target, its mechanism of action is not publicly characterized.
AMG 256 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. The company is conducting clinical research on this investigational oncology drug.
AMG 256 is in Phase 1 clinical development. One Phase 1 study has been completed, which enrolled 34 adult subjects with advanced solid tumors. The drug is investigational and has not received FDA approval.
AMG 256 has one completed clinical trial, NCT04362748, titled "Study of AMG 256 in Adult Subjects With Advanced Solid Tumors." This Phase 1 study enrolled 34 participants across the United States, Australia, Belgium, and Spain.
No alternative names for AMG 256 have been disclosed. It is identified solely by its development code AMG 256 and is being studied as a monotherapy in advanced solid tumors.